|

Vepugratinib Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Also known as: LOXO-435, LY3866288

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • Eli Lilly and Company2

Indications

  • Urinary Bladder Neoplasms2
  • Neoplasm Metastasis2
  • Cancer2
  • Ureteral Neoplasms1
  • Carcinoma, Transitional Cell1

Huntsville, Alabama1 trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Clearview Cancer Institute

Phase 3

Tucson, Arizona1 trial

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

University of Arizona - Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.